1989
Journal of Cardiopulmonary Rehabilitation
Author Index

Allen RE, 195
Amarosa-Tupler B, 348
Andres FF, 145
Arnold N, 115
Auchincloss JH, 87

Bahl RA, 460
Balady GJ, 35
Bates E, 237
Beckman RJ, 316
Ben-Ari E, 281
Benson H, 316
Blevins W, 243
Blumenthal JA, 46
Borkgren MW, 63
Boston A, 237
Boucher TM, 465
Brammell HL, 250
Braun JQ, 439
Braun KL, 72
Brooks CJ, 72
Brown, RA, 155
Brown SE, 155, 183
Bruce RA, 24

Campbell RB, 303
Carida RV, 348
Carmichael M, 195
Carter CL, 356
Carter R, 243
Chetty, KG, 183
Chong-Xuan G, 341
Clark PL, 243
Conti R, 195
Cottington E, 286
Crosby L, 286
Crouse SF, 202

Daltroy LH, 363
Deckro JP, 316
Dow-Conklin D, 115
Dressendorfer RH, 341
Duncan JJ, 110, 325

Emergy CF, 46

Farr JE, 110
Fischer CE, 155
Fletcher BJ, 207
Fletcher GF, 207
Freedson PS, 122
Freeman D, 237
Friedman R, 316
Froelicher VF, 143, 479

Gagas B, 237
Gerstenblith G, 12
Gilbert R, 87
Godin G, 223, 363
Golding LA, 486
Gordon NF, 110, 325
Graves JE, 195
Greninger LO, 145
Guarracini M, 237
Gurry MK, 122

Hahn LP, 448
Hallam CC, 281
Haskell WL, 448
Hasson S, 202
Hillis SJ, 281
Hills R, 273
Hopp JW, 273
Hossack KF, 40

Jacobs DR Jr, 448
Janelli LM, 492

Kaminsky LA, 263
Kavanagh T, 303
Keyser RE, 145
King, ML, 237
Kinsey MG, 207
Kline G, 122
Knoll SF, 72
Kohl HW, 110, 325

La Ham-Saeger J, 263
Landes JR, 439
Landin RJ, 281
Larson EB, 24
Leach CN Jr, 115
Leaf DA, 460, 497
Lee JW, 273
Lehmann KG, 479
Lennihan L, 237
Leserman J, 316
Lesmes GR, 263
Light, RW, 155
Light RW, 183
Linnemeir TJ, 281
Linsenbardt S, 243

Mamish ME, 316
Mangus BC, 486
McAfee SR, 497
Mertens DJ, 303
Meyer K, 164
Milne N, 183
Miranda CP, 479
Monpere C, 161
Morales R, 87
Morse, DE, 145

Nequin ND, 263
Nicotra B, 243
Noble JR, 281
Nori S, 237
Nygaard P, 268

Parcels JA, 72
Parker DL, 497
Pasternak RC, 465
Paternostro-Bayles M, 286
Peppi D, 87
Pescatello LS, 115
Peterson RA, 103
Pickett KP, 325
Pifalo WB, 286
Pinder SL, 46
Pirie P, 448
Pollock ML, 195
Porcari J, 122

Rambusch JM, 311
Rehm LM, 439
Reis GJ, 465
Rice CR, 207
Rippe JM, 122
Rod JL, 439
Rothbaum DA, 281
Rowland TW, 311
Runke JA, 263

Saeterhaug A, 268
Sarma RJ, 460
Sawyer P, 303
Schaffer W, 263
Scherer YK, 492
Schmieder LE, 492
Schulman SP, 12
See MR, 281
Shephard RJ, 17, 188
Shiner R, 281
Siconolfi SS, 311
Sidney S, 448
Smith LK, 379
Staab JS, 311
Stansbury DW, 155
Steinmetz EF, 281
Sterling J, 202
Stratton BF, 80
Stratton J, 24
Stuart EM, 316

Tapp JT, 348
Tennant LK, 195
Timmis GC, 341
Tolson H, 202
Tran ZV, 250

Unnithan VB, 311

Vaandrager H, 110, 325
Van Camp SP, 103
Villegas JA, 325

Ward A, 122
Warkentin D, 145
Watson PH, 207
Weidemann H, 164
Weiner DA, 35
Wenger NK, 9
Wolfel EE, 40

Yacoub M, 303
Yen RS, 445

1989
Journal of Cardiopulmonary Rehabilitation
Subject Index

β-Adrenergic blockade. *See* Beta-blockers
Aerobic capacity, variations in, 24–33
Aging
cardiovascular changes in, 12–15
and exercise for elderly persons, 9–11. *See also* Exercise training, for elderly persons
American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)
abstracts of fourth annual meeting, 392–426
issues in use of rehabilitation programs, 379–380
Angina pectoris, and stress management with relaxation and imagery, 348–355
Angioplasty, percutaneous transluminal, and restenosis rate after rehabilitation program, 281–285
Aortic blood flow velocity during exercise, 356–362
Arm ergometry compared to treadmill testing, 145–153
Atrial hypertrophy, right, and false positive exercise tests, 161–163

Behavior modification
effectiveness of interventions in, 223–235
and home-monitored exercise program, 207–211
in hypertension, 316–323
Beta-blockers
and heart rate recovery from exercise, 202–206
and improved treadmill test sensitivity, 341–346
and serum lipids during exercise training in hypertension, 110–113
Bioimpedance, thoracic, and cardiac output measurements in exercise, 311–315
Blood flow velocity, aortic, during exercise, 356–362
Blood pressure
in hypertension
and drug therapy affecting lipid levels in exercise training, 110–113
nonpharmacologic intervention in, 316–323
leisure-time activity affecting, 497–504
Book reviews, 23

Caffeine ingestion, and responses to exercise testing, 460–464
Carbon dioxide equilibrium rebreathing for cardiac output estimation, 87–91
automated system for, 122–126
CARDIA study, physical activity history in, 448–459
Cardiac output measurements
automated system for output at rest, 122–126
equilibrium CO_2 rebreathing method in, 87–91
thoracic bioimpedance in, during exercise, 311–315
Cholesterol. *See* Lipid levels
Circuit training with resistance equipment, rest interval duration in, 325–330
Cocaine use, and coronary artery disease, 445–447
Compliance of patients
and coronary risk factor modification, 207–211
spousal social support affecting, 363–367
Contraceptive use, oral, and psychosocial factors in females with myocardial infarction, 164–171
Coronary artery disease
and cocaine use, 445–447
and effects of early and late admissions to rehabilitation program, 72–78
exercise testing in. *See* Exercise testing
infarction with. *See* Myocardial infarction
risk factors in. *See* Risk factors
simulated work activity in, 439–444
treatment affecting responses to exercise, 24–33
Cycle ergometer, heart rate-controlled, 195–200

Dead space, and ventilatory reserve at exhaustion, 155–159
Diet
behavior modification in
effectiveness of interventions in, 223–235
four-year follow-up study of, 207–211
and fish oil affecting lipid levels, 465–468

Editorial, 143-144
Educational programs
effectiveness in coronary heart disease, 223–235
followed by home-monitored exercise, 207–211
in hypertension, 316–323
in New Britain Cardiac Rehabilitation Program, 115–120
after percutaneous transluminal coronary angioplasty, 281–285
in pulmonary rehabilitation, 80–85
diversity in, 63–70
effectiveness of, 492–496
knowledge tests in, 273–279
Elderly persons
exercise testing in, 35–39
exercise training for, 9–11
cardiac responses to, 12–15
and effects of coronary heart disease treatment, 31–33
guidelines for, 40–45
perception of exertion in, 17–22
physical fitness and aerobic capacity affecting, 24–30
psychological effects of, 46–51
Employment
and return to work after myocardial infarction, 268–271
and simulated work activity after cardiac events, 439–444
Equilibrium CO_2 rebreathing for cardiac output estimation, 87–91
automated system for, 122–126
Ergometry. *See* Exercise testing
Erratum, 280
Exercise
aortic blood flow velocity in, 356–362
behavior modification in
effectiveness of interventions in, 223–235
in home-monitored program, 207–211
capacity in pulmonary disease with right ventricular dysfunction, 183–186
competing in varsity athletics after cardiac transplantation, 486–491
and heart rate recovery affected by beta-blockade, 202–206
leisure-time activity and coronary artery risease risk, 497–504
ultramarathon race affecting lipid levels, 263–267
and validity of short physical activity history, 448–459
Exercise testing
caffeine ingestion affecting, 460–464
cardiac output measurements in
equilibrium CO_2 rebreathing method in, 87–91
thoracic bioimpedance in, 311–315
in elderly persons, 35–39
false positive tests in right atrial hypertrophy, 161–163
gas exchange in, and work performance in pulmonary disease, 243–247
in hemiparesis, 237–241
improved test sensitivity in beta-blockage, 341–346
sensitivity of arm and treadmill tests, 145–153
survey of Veterans Administration hospitals, 479–485
and ventilatory reserve at exhaustion, 155–159
Exercise training
after cardiac transplantation, 303–310
cost/benefit analysis in cardiac rehabilitation, 188–193
and drug therapy affecting lipid levels in hy-

pertension, 110–113
for elderly persons, 9–11
cardiac responses to, 12–15
and effects of coronary heart disease treatment, 31–33
guidelines for, 40–45
perception of exertion in, 17–22
physical fitness and aerobic capacity affecting, 24–30
psychological effects of, 46–51
heart rate-controlled cycle ergometer in, 195–200
home-monitored, and coronary risk factor modification, 207–211
and identification of high-risk cardiac patients, 103–109
and lipid levels after myocardial infarction, 250–254
in New Britain Cardiac Rehabilitation Program, 115–120
and rest interval duration in hydraulic resistance circuit training, 325–330
and restenosis after percutaneous transluminal coronary angioplasty, 281–285
and return to work after myocardial infarction, 268–271
after right ventricular infarction, 286–290
spousal social support in, 363–367

Fish oil therapy, and cholesterol levels, 465–468

Gas exchange, and work performance in pulmonary disease, 243–247

Heart rate
control by cycle ergometer, 195–200
recovery from exercise affected by beta-blockers, 202–206
Help Yourself to Better Breathing Program, 492–496
Hemiparesis, exercise testing in, 237–241
Hemodynamic measurements in arm ergometry and treadmill testing, 145–153
High-risk cardiac patients, identification of, 103–109
Home exercise program, and coronary risk factor modification, 207–211
Hydraulic resistance circuit training, rest interval duration in, 325–330
Hypertension
and drug therapy affecting lipid levels in exercise training, 110–113
nonpharmacologic intervention in, 316–323
Hypertrophy of right atrium, and false positive exercise tests, 161–162

Imagery, and stress management in angina pectoris, 348–355
In the literature, 92–93, 173–174, 292–294, 368–369

Letters to the editor, 131–132, 470
Lipid levels
and effects of drug therapy during exercise training in hypertension, 110–113
exercise training affecting, after myocardial infarction, 250–254
fish oil therapy affecting, 465–468
leisure-time activity affecting, 497–504
and psychosocial factors in females with myocardial infarction, 164–171
ultramarathon race affecting, 263–267
Lung disease
gas exchange and work performance in, 243–247
and oxygen consumption in right ventricular dysfunction, 183–186
rehabilitation in. *See* Pulmonary rehabilitation

Metoprolol, and treadmill test sensitivity, 341–346
Minnesota Heart Health Program, physical activity history in, 448–459
Myocardial infarction
exercise training after, affecting lipid levels, 250–254
return to work after, 268–271
right ventricular, and outpatient rehabilitation, 286–290
and risk factors related to psychosocial stress in females, 164–171

Nadolol, and treadmill test sensitivity, 341–346
New Britain Cardiac Rehabilitation Program, 115–120
New products and services, 95–96, 127–128, 331–332, 506–507

Omega-3 fatty acids affecting cholesterol levels, 465–468
Oxygen
consumption in pulmonary disease with right ventricular dysfunction, 183–186
uptake of
in chronic obstructive pulmonary disease, 243–247

Physical activity. *See* Exercise
Pindolol, and serum lipids during exercise training in hypertension, 110–113
Propranolol
and heart rate recovery from exercise, 202–206
and serum lipids during exercise training in hypertension, 110–113
and treadmill test sensitivity, 341–346
Psychological aspects
of exercise in elderly cardiac patients, 46–51
and management of stress
in angina pectoris, relaxation and imagery in, 348–355
and relaxation response affecting blood pressure, 316–323
and stress related to risk factors in females with myocardial infarction, 164–171
Pulmonary disease
gas exchange and work performance in, 243–247
and oxygen consumption in right ventricular dysfunction, 183–186
Pulmonary function, and ventilatory reserve at echaustion, 155–158
Pulmonary rehabilitation
beneficial effects of REACH program, 80–85
diversity in, 63–70
in Help Yourself to Better Breathing Program, 492–496
knowledge tests for evaluation of programs, 273–279

REACH pulmonary rehabilitation program, benefits of, 80–85
Rebreathing of CO_2 for cardiac output estimation, 87–91 automated system for, 122–126
Relaxation techniques
affecting blood pressure, 316–323
and stress management in angina pectoris, 348–355
Risk factors
behavior modification of
effectiveness of interventions in, 223–235
and home-monitored exercise program, 207–211
in hypertension, 316–323
and identification of high-risk cardiac patients, 103–109
and psychosocial stress in females with myocardial infarction, 164–171
relation to leisure-time physical activity, 497–504
Running, and ultramarathon race affecting lipid levels, 263–267

Smoking
behavior modification in
effectiveness of interventions in, 223–235
four-year follow-up study of, 207–211
and psychosocial factors in females with myocardial infarction, 164–171
Spousal approval, and participation in exercise program, 363–367
Stress
management of
in angina pectoris, relaxation and imagery in, 348–355
and relaxation response affecting blood pressure, 316–323
psychosocial, related to risk factors in females with myocardial infarction, 164–171
Sympathomimetic activity of drugs, and serum lipids during exercise training in hypertension, 110–113
Thoracic bioimpedance, and cardiac response to exercise, 311–315
Transplantation, cardiac
competing in varsity athletics after, 486–491
exercise training after, 303–310
Treadmill exercise
compared to arm ergometry, 145–153
improved test sensitivity in beta-blockade, 341–346
Triglycerides. *See* Lipid levels

Ultramarathon race affecting lipid levels, 263–267

Ventilatory reserve at exhaustion, 155–159
Ventricle, right
dysfunction in pulmonary disease, and maximal oxygen consumption, 183–186
infarction of, and outpatient rehabilitation, 286–290
Veterans Administration hospitals, exercise testing in, 479–485

Wind-braked ergometer for exercise testing in hemiparesis, 237–241
Women with myocardial infarction, and psychosocial context of risk factors, 164–171
Work activity
and return to work after myocardial infarction, 268–271
simulated, after cardiac events, 439–444